[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100565233":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":35,"centralContacts":39,"locations":45,"responsibleParty":62,"collaborators":26,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":26,"eligibilityCriteria":70,"healthyVolunteers":67,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":26,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":86,"whyStopped":26,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"The First Affiliated Hospital of Nanchang University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention group","EXPERIMENTAL","Bifidobacterium longum capsules (10\\^10 CFU) twice daily for 14 days",[13,14],"Dietary Supplement: Bifidobacterium longum","Combination Product: Standard clinical treatment",{"label":16,"type":17,"description":18,"interventionNames":19},"Placebo group","PLACEBO_COMPARATOR","Placebo capsules twice daily for 14 days",[20,14],"Dietary Supplement: Placebo",[22,27,30],{"type":23,"name":24,"description":24,"armGroupLabels":25,"otherNames":26},"DIETARY_SUPPLEMENT","Bifidobacterium longum",[9],null,{"type":23,"name":28,"description":28,"armGroupLabels":29,"otherNames":26},"Placebo",[16],{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":26},"COMBINATION_PRODUCT","Standard clinical treatment","Fasting, gastrointestinal decompression, rehydration, inhibition of pancreatic fluid and pancreatic enzyme secretion, improvement of microcirculation, and support of organ function if organ dysfunction occurs at a later stage (mechanical ventilation, continuous renal replacement therapy, and the use of vasoactive drugs).",[9,16],[36],{"name":37,"affiliation":5,"role":38},"Cong He, PhD","PRINCIPAL_INVESTIGATOR",[40],{"name":41,"role":42,"phone":43,"phoneExt":26,"email":44},"yin zhu, PhD","CONTACT","+8613970847464","ndyfy01977@ncu.edu.cn",[46],{"facility":5,"status":26,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Nanchang","Jiangxi","330006","China","CN",{"type":53,"coordinates":54},"Point",[55,56],115.85306,28.68396,{"lat":56,"lon":55},[59],{"name":37,"role":42,"phone":60,"phoneExt":26,"email":61},"+8613807032823","hecong.1987@163.com",{"type":38,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Lingyu Luo","Professor","100565233","therapeutic-effect-of-bifidobacterium-longum-in-patients-with-acute-pancreatitis-a-randomized-double-blind-placebo-controlled-trial-100565233",false,"NCT06639516","Therapeutic Effect of Bifidobacterium Longum in Patients with Acute Pancreatitis: a Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n1. Age 18-75 year;\n2. The diagnosis of acute pancreatitis according to the revised Atlanta classification;\n3. The onset time of acute pancreatitis is within 48 hours;\n4. APACHE II score of ≥8, or C-reactive protein \\> 150 mg\u002FL, or SIRS score of ≥3;\n5. Signed the informed consent.\n\nExclusion Criteria:\n\n1. Within 48 hours of onset, there is multi-organ failure;\n2. Use of probiotics within the last month;\n3. Pancreatitis following endoscopic retrograde cholangiopancreatography (ERCP);\n4. Intra-operative diagnosis;\n5. Infection\u002Fsepsis caused by a second disease;\n6. Malignancy;\n7. Immunocompromised patients;\n8. Pregnancy and\u002For lactation;\n9. Allergy to Bifidobacterium longum.","ALL","18 Years","75 Years",{"count":75,"type":76},60,"ESTIMATED","INTERVENTIONAL",[79],"NA","The purpose of this clinical trial is to investigate the impact of Bifidobacterium longum(BL) on the clinical prognosis of patients with acute pancreatitis(AP), to analyze the correlation between BL and intestinal barrier function, as well as the gut microbiota, and to observe adverse reactions and risks in patients with AP after the use of BL.\n\nParticipants will be randomly assigned to two groups: the intervention group and the control group. They will receive:\n\n* Intervention group: Standard clinical treatment + BL capsules (10\\^10 CFU), twice a day, for a total of 14 days;\n* Control group: Standard clinical treatment + placebo capsules, for a total of 14 days.\n\nA total of 60 patients will be included in this study.",[82],"Acute Pancreatitis",[84,85],"acute pancreatitis","Probiotics","NOT_YET_RECRUITING","2025-02-04",{"date":89,"type":90},"2025-02-06","ACTUAL",{"date":92,"type":76},"2025-02-15",{"date":94,"type":76},"2025-12-01",{"name":5,"class":6},1]